LM-168 alone or combined with toripalimab for advanced solid tumors

A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

This trial tests whether LM-168, given alone or together with the immunotherapy toripalimab, can shrink tumors or control disease in adults with advanced solid tumors.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 87 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: LaNova Medicines Limited (Industry-sponsored)
• Drugs / interventions: immunotherapy, radiation, prednisone, toripalimab
• Locations: 6 sites (Ryde, New South Wales and 5 other locations)
• Trial ID: NCT06868199 on ClinicalTrials.gov

What this trial studies

This phase 1/2 interventional trial starts with a phase I dose-escalation to determine safety, tolerability, and the recommended phase 2 dose or maximum tolerated dose of LM-168 alone or in combination with toripalimab. In phase II the trial measures preliminary anti-tumor activity using objective response rate in selected advanced solid tumors. Eligible adults must have histologically or cytologically confirmed advanced solid tumors with measurable disease and adequate organ function, and most will have progressed on or be ineligible for standard therapies. Optional archival or on-treatment biopsies may be collected for biomarker analysis.

Who should consider this trial

Good fit: Adults (≥18) with recurrent or refractory advanced solid tumors, ECOG performance status 0–1, measurable disease, adequate organ and marrow function, and who have progressed on or lack standard therapies are the intended participants.

Not a fit: Patients with poor performance status (ECOG ≥2), life expectancy under three months, significant uncontrolled organ dysfunction, or those who have effective standard therapy available are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, LM-168 alone or with toripalimab could provide a new treatment option that shrinks tumors or prolongs disease control for some patients with advanced solid tumors.

How similar studies have performed: Combining novel agents with PD‑1 inhibitors has produced benefits in some cancer types, but LM‑168 is a new agent and this exact combination with toripalimab is experimental and not yet proven.

Eligibility criteria

Inclusion Criteria:

1. Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
2. Aged ≥18 years old (including boundary values) , male or female.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Life expectancy ≥ 3 months.
5. In dose escalation stage, subjects must have histological or cytological confirmation of recurrent or refractory advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
6. In dose expansion stage, subjects must have histological or cytological confirmation of selected advanced solid tumors.
7. Pre-treatment archived tumour tissue or on-treatment tumour biopsy could be provided for biomarker analysis optionally.
8. At least one measurable disease.
9. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
10. Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion Criteria:

1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-168.
2. Having received prior anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 28 days of commencing treatment with LM-168 or experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
3. Subjects who have received the anti-tumor treatments within the specified time periods prior to the first dosing of LM-168.
4. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
5. Subjects with uncontrolled tumour-related pain.
6. Subjects with known central nervous system (CNS) or meningeal metastasis.
7. Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
8. Subjects with esophageal or gastric varices requiring immediate intervention, or those with a history of variceal bleeding.
9. Hepatic encephalopathy, hepatorenal syndrome, Child-Pugh class B or more severe liver cirrhosis.
10. Tumor invasion of surrounding vital organs or a risk of developing esophagotracheal fistula or esophagopleural fistula.
11. Patients with a history of active or previously confirmed inflammatory bowel disease.
12. Subjects who experienced grade 3 or higher hypersensitivity to the treatment that contains monoclonal antibody.
13. Subjects who previously experienced grade ≥ 3 immune-related adverse events during immunotherapy, as well as subjects who discontinued prior immunotherapy due to severe or life-threatening immune-related adverse events.
14. Subjects who take systemic corticosteroids (\> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dosing of LM-168.
15. Subjects with the known history of autoimmune disease.
16. Subjects with the history of idiopathic pulmonary fibrosis, organizing pneumonia , drug-induced pneumonitis, idiopathic pneumonitis, interstitial lung disease, severe radiation pneumonitis or evidence of active pneumonitis on screening chest CT scan.
17. Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-168.
18. Current or recent use of aspirin (\> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
19. Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for \> 2 weeks prior to the first dose of LM-168.
20. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-168 (excluding tumour biopsy, puncture, etc.).
21. Subjects who have severe cardiovascular disease.
22. Subjects who have uncontrolled or severe illness.
23. Subjects who have a history of immunodeficiency disease.
24. HIV infection, active infection including tuberculosis, HBV and HCV infection.
25. Subjects with a history of other malignancies within 5 years prior to the first administration of the study drug.
26. Child-bearing potential female who have positive results in pregnancy test or are lactating.
27. Subjects who have psychiatric illness or disorders that may preclude study compliance.
28. Subject who is judged as not eligible to participate in this study by the investigator.

Where this trial is running

Ryde, New South Wales and 5 other locations

• Macquarie University — Ryde, New South Wales, Australia (Recruiting)
• MUPharm Pty Limited trading as Macquarie University Hospital Parmarcy — Ryde, New South Wales, Australia (Recruiting)
• Cancer Care Wollongong Pty Limited — Wollongong, New South Wales, Australia (Recruiting)
• Bayview Health-Investigational Drug Services — Perth, Western Australia, Australia (Recruiting)
• One Clinical Reasearch — Perth, Western Australia, Australia (Recruiting)
• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (Not_yet_recruiting)

Study contacts

• Study coordinator: Alex Yuan

Conditions Advanced Solid Tumours